Population pharmacokinetic analysis of blood concentrations of robenacoxib in dogs with osteoarthritis.
The purpose of this analysis was to investigate whether the recommended daily dosage of 1-2mg/kg robenacoxib provides consistent exposure when administered to dogs with chronic osteoarthritis (OA), and the need for dose adjustment in special patient populations. Data from three prospective, multi-center field studies in 208 OA dogs were analyzed using non-linear mixed effects modeling. A model based assessment was performed with stepwise inclusion and exclusion of population characteristics to explain between-subject variability, and assess the according necessity for dose adjustment. Only the influence of bodyweight on both apparent clearance and volume were found to be significant (p<0.01). No significant influence of sex, age and breed, or kidney and liver variables was identified in this representative sample of OA dogs. The population pharmacokinetic analysis performed showed that the 1-2mg/kg dosage chosen provided consistent robenacoxib exposure in a wide range of canine patients. No other dose adjustment seems necessary.
['Fink|M|M|', 'Letellier|I|I|', 'Peyrou|M|M|', 'Mochel|J P|JP|', 'Jung|M|M|', 'King|J N|JN|', 'Gruet|P|P|', 'Giraudel|J M|JM|']
D000818:Animals D000894:Anti-Inflammatory Agents, Non-Steroidal D001835:Body Weight D002908:Chronic Disease D004159:Diphenylamine D004283:Dog Diseases D004285:Dogs D005260:Female D008297:Male D010003:Osteoarthritis D010648:Phenylacetates D012737:Sex Factors
Population pharmacokinetics Robenacoxib Dog osteoarthritis OA AUC BLQ COX COXIB EBEs FOCE IIV IOV LLOQ NSAID OFV RSE area under the curve below limit of quantification cyclooxygenase empiricial Bayes estimates first order conditional estimation method inter-individual variability inter-occasion variability lower limit of quantification non-steroidal anti-inflammatory drug objective function value relative standard error